seperator

About Ethris

seperator

 

seperator

About Ethris

seperator

 

A SHORT INTRODUCTION

Based in the biotech hub of Martinsried just outside Munich, Germany, Ethris was founded by Dr. Carsten Rudolph and Prof. Christian Plank in 2009 to develop messenger RNA as a new drug modality. The company’s focus is to develop products based on its’ proprietary SNIM®RNA technology to treat patients with respiratory disorders. Ethris has developed a pipeline of Transcript Therapies for rare and genetic respiratory diseases, and is working with partners to advance programs for other respiratory diseases and for non-respiratory conditions.

The potential applications of messenger RNA-based therapies are too numerous for a single company to pursue. As a result, Ethris is focused internally on a strategic set of respiratory disorders, and works with partners to realize the potential for its patented SNIM®RNA Transcript Therapies in other areas of human disease. Learn more about our technology.

ETHRIS IS PAVING A NEW PATH FROM GENES TO THERAPEUTIC PROTEINS USING OUR PROPRIETARY MESSENGER RNA TECHNOLOGY.

ETHRIS IS PAVING A NEW PATH FROM GENES TO THERAPEUTIC PROTEINS USING OUR PROPRIETARY MESSENGER RNA TECHNOLOGY.

READ MORE

Learn more about our technology.

LEARN MORE